Doctors are hopeful a new version of a drug could help hepatitis C sufferers. Two studies, sponsored by the drug maker Hoffmann-La Roche Inc, tested a modified form of interferon called Pegasys against the standard Roferon-A.
The findings show that Pegasys is more effective and has fewer side effects.
There are four million Americans infected with hepatitis C, which can cause liver inflammation, cirrhosis, and cancer. The standard treatment for the disease has been injections of interferon alpha or a combination of interferon and another antiviral drug ribavirin.
Hoffmann-La Roche has applied for Food and Drug Administration approval to sell Pegasys. Schering-Plough Corp. is also looking for approval on a similarly modified interferon, Peg-Intron. Studies using Peg-Intron show it to be effective in 54% of patients.
Information from www.usatoday.com.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.